Catalent (NYSE:CTLT) has been assigned an average rating of “Buy” from the eighteen analysts that are presently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $46.00.
Several research analysts have issued reports on CTLT shares. Goldman Sachs started coverage on Catalent in a research note on Wednesday, January 24th. They set a “buy” rating and a $50.00 price objective for the company. Royal Bank of Canada set a $48.00 price objective on Catalent and gave the stock a “buy” rating in a research note on Monday, February 5th. Stephens lowered Catalent from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, February 6th. Bank of America increased their price objective on Catalent from $47.00 to $49.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Finally, ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th.
Catalent stock traded up $0.73 during mid-day trading on Friday, hitting $40.22. 777,659 shares of the company were exchanged, compared to its average volume of 830,033. The company has a debt-to-equity ratio of 2.53, a current ratio of 2.18 and a quick ratio of 1.78. Catalent has a 1-year low of $33.35 and a 1-year high of $47.87. The firm has a market capitalization of $5.36 billion, a P/E ratio of 29.79, a P/E/G ratio of 2.14 and a beta of 1.53.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, May 1st. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.06. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The firm had revenue of $627.90 million during the quarter, compared to analyst estimates of $610.47 million. During the same period in the prior year, the company posted $0.38 earnings per share. The business’s revenue for the quarter was up 17.9% compared to the same quarter last year. equities research analysts predict that Catalent will post 1.55 EPS for the current fiscal year.
In other news, SVP William Downie sold 9,082 shares of the firm’s stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the sale, the senior vice president now directly owns 46,986 shares in the company, valued at $1,964,014.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.70% of the company’s stock.
Large investors have recently made changes to their positions in the company. Xact Kapitalforvaltning AB increased its position in Catalent by 65.7% in the first quarter. Xact Kapitalforvaltning AB now owns 20,690 shares of the company’s stock worth $850,000 after purchasing an additional 8,200 shares during the period. Legal & General Group Plc increased its position in Catalent by 15.4% in the first quarter. Legal & General Group Plc now owns 162,268 shares of the company’s stock worth $6,663,000 after purchasing an additional 21,621 shares during the period. Foundry Partners LLC increased its position in Catalent by 26.3% in the first quarter. Foundry Partners LLC now owns 42,387 shares of the company’s stock worth $1,740,000 after purchasing an additional 8,827 shares during the period. Segall Bryant & Hamill LLC increased its position in Catalent by 66.4% in the first quarter. Segall Bryant & Hamill LLC now owns 365,886 shares of the company’s stock worth $15,023,000 after purchasing an additional 145,941 shares during the period. Finally, Kiwi Wealth Investments Limited Partnership acquired a new stake in Catalent in the first quarter worth about $2,552,000.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.